MedTrace Logo

PROpranolol for Cerebral Hemorrhage-ASsociated pnEumonia (PRO-CHASE)

NCT05419193 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 168

Last updated 2025-07-14

No results posted yet for this study

Summary

Stroke-associated pneumonia (SAP) is a grave complication of stroke and one of the most important predictors for patients' poor outcomes. Stroke associated pneumoniaSAP and other infections limited the overall efficacy of stroke management. Increasing evidence suggests that sympathetic nervous system activity contributes to post post-stroke immunosuppression and emergence of infections. This study is designed to test the safety and efficacy of an adrenergic β receptor blocker propranolol in reducing SAP in hemorrhagic stroke patients, in a multi-center, randomized, open-labeled, end point-blinded, trial.

Conditions

  • Stroke
  • Vascular Accident
  • Intracranial Hemorrhages
  • Intracerebral Hemorrhage
  • Hemorrhagic Stroke
  • Stroke, Acute

Interventions

DRUG

Propranolol Hydrochloride

Day of randomization: propranolol IV vp for 7 days after randomization

OTHER

control group

Patients will receive usual care and drug use in hospital

Sponsors & Collaborators

  • Beijing Tiantan Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-21
Primary Completion
2024-12-18
Completion
2025-03-11

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05419193 on ClinicalTrials.gov